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Every drug comes with some side effect. It is the benefit/risk ratio that determines the medical use of the drug. Quinine, a known
antimalarial drug, has been used for nocturnal leg cramps since the 1930s; it is associated with severe life-threatening hematological
and cardiovascular side effects. Disseminated intravascular coagulation (DIC), albeit rare, is a known coagulopathy associated with
Quinine. It is imperative to inquire about the Quinine intake in medication history in patients with coagulopathy, as most patients
still consider it a harmless home remedy for nocturnal leg cramps. In this report, we present a case of coagulopathy in amiddle-aged
woman, who gave a history of taking Quinine for nocturnal leg cramps, as her home remedy. Early identification of the offending
agent led to the diagnosis, prompt discontinuation of the medication, and complete recovery and prevented the future possibility
of recurrence.
1. Introduction
Quinine has been used widely for idiopathic leg cramps since
the 1930s [1, 2]. However, it has been implicated in some
grave and life-threatening adverse events, such as thrombocy-
topenia, hypersensitivity reaction, and prolongedQT interval
on electrocardiography [3]. Currently in the United States,
Quinine is a prescription medication, approved by the Food
and Drug Administration (FDA), solely, to be used for the
treatment of uncomplicated malaria, caused by the parasite
Plasmodium falciparum, primarily, in travellers returning
from the malaria-endemic areas [4]. Despite the warning
against the off-labelled use of Quinine, the FDA estimated
some 51,800 patients receiving dispensed prescription for
Quinine from the US outpatient retail pharmacies during
the year 2011 only. So, the serious adverse effects may still
continue to be reported [3]. In this corresponding study, we
are reporting a case of a 45-year-old woman, who developed
disseminated intravascular coagulation (DIC), after taking
Quinine pills for night cramps.
2. Case Presentation
A45-year-old female, with a priormedical history of essential
hypertension, anxiety, and IgA nephropathy with a normal
renal function, presented to the emergency department
with palpitations, light-headedness, abdominal pain, nausea,
vomiting, and diarrhea.
Symptoms started about 4 hours after she took two tablets
of Quinine 324mg each, which she got from her mother for
nocturnal leg cramps.
She had no cough, dysuria, hematuria, headache, hema-
temesis, hematochezia, or melena.
She is taking amlodipine for hypertension and alprazolam
for anxiety, and there is no recent change in her medications.
She quit smoking about 15 years ago; she denies alcohol
or illicit drugs use.
There was no family history of hematological diseases.
Further history revealed that she had a similar episode
of palpitations five months ago, after taking Quinine tablets.
At that time, she was admitted to the hospital, where lab
tests showed prolonged prothrombin time (PT), international
normalized ratio (INR), activated partial thromboplastin
time (aPTT), and elevated D-dimer level, with a normal
platelet count. However, no explanation was found at that
time for these findings, as nobody had linked her symptoms
and lab findings to Quinine intake.
Examination revealed alert and oriented, middle-aged
woman, who was not in acute distress, she had mild dehy-
dration, heart rate was 167 beats/minute, blood pressure
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Table 1: Lab results on admission and most deranged value at discharge and six weeks after discharge.
Laboratory test (ref range & units) On admission
Most deranged
value during
admission
At discharge At 6 weeks afterdischarge
White blood cells (4.0–10.8 K/UL) 2.1 × 109 cells/L 2.1 × 109 cells/L 6.3 × 109 cells/L 6.1 × 109 cells/L
Haemoglobin (12.0–16.0G/DL) 15.8 gm/dL 11.2 gm/dL 11.9 gm/dL 13.0 gm/dL
Platelets (130–430K/UL) 233 × 109 cells/L 8.1 × 109 cells/L 130 × 109 cells/L 268 × 109 cells/L
Neutrophil (36–75%) 35% 35% 58% 58%
Lymphocyte (20–50%) 34% 2% 32% 30%
Blood urea nitrogen (6–20MG/DL) 21mg/dL 21mg/dL 8mg/dL 14mg/dL
Creatinine (0.5–1.1MG/DL) 1.2mg/dL 1.0mg/dL 1.0mg/dL 1.0mg/dL
Prothrombin time (PT) (12.0–14.7 seconds) 19.4 seconds 25.5 seconds 14.3 seconds 12.9 seconds
International normalized ratio (INR) (<4.0) 1.68 2.38 1.33 0.99
Partial thromboplastin time (aPTT) (23.3–35.7 seconds) 49.9 seconds 76.5 seconds 25.6 seconds 27.7 seconds
D-dimer level (0–499NG/ML) >10,000.00 ng/dL — — —
Fibrinogen (193–473MG) 69mg 69mg 291mg 359mg
Lactate dehydrogenase (100–225U/L) 584U/L — — 145U/L
Haptoglobin (16–200MG/DL) 5.8mg/dL — — —
Reticulocytes (0.5–2.0%) 3.88% — — —
was 123/80mmHg and respiratory rate was 28/minute, the
temperature was 39.5 Celsius, she had no ecchymosis but had
diffuse abdominal tenderness, without rebound tenderness or
hepatosplenomegaly, and the rest of the general physical and
systemic examination was normal.
She was admitted to the intensive care unit and treated
initially as DIC possibly due to sepsis or drug induced.
2.1. Investigation. Electrocardiogram showed sinus tachycar-
dia with a heart rate of 151 beats/minute.
Complete blood count, coagulation profile, and other
relevant laboratory findings are given in Table 1.
With the conglomeration of many coagulation defects,
prolonged PT, aPTT, increased INR, and D-dimer level,
associated with decreased level of fibrinogen, in addition to
anemia, leucopenia, and thrombocytopenia, all these were
consistent with the diagnosis of disseminated intravascular
coagulation. Peripheral blood smear was normal and no
schistocytes were found.The coagulopathyworsened to nadir
for the next 48 hours before showing any improvement.
Levels of liver transaminase, bilirubin, alkaline phos-
phatase, and thyroid function were within normal limits.
Direct globulin test was positive but test for Quinine-induced
platelet autoantibodies was not done. Urine toxicology screen
was negative for any illicit drug.
Chest X-ray, urinalysis, and blood and urine cultures
remained negative.
Antinuclear antibodies (ANA) were negative and lupus
anticoagulant was undetected.
2.2. Differential Diagnosis. Thedifferential diagnosis includes
conditions associated with bleeding tendency, hypercoagu-
lability, other causes of microangiopathic hemolytic anemia
(MAHA), and thrombocytopenia:
(i) Thrombotic thrombocytopenic purpura (TTP).
(ii) Hemolytic uremic syndrome (HUS).
(iii) Sepsis.
(iv) Severe liver disease.
(v) Autoimmune diseases like systemic lupus erythema-
tous (SLE) and antiphospholipid syndrome.
(vi) Certain drugs and herbal supplement adverse effect.
(vii) Neoplastic conditions: leukemia, lymphoma, and
myelodysplastic syndrome.
Coagulation tests revealed prolonged PT and aPTT with
decreased fibrinogen. Unlike DIC, patients with TTP or
HUShave normal coagulation testing, becausemicrovascular
thrombi in these conditions are primarily platelet-rich and
fibrin-poor thrombi and are not associatedwith consumption
coagulopathy. Besides, Patient has no neurologicalmanifesta-
tions and renal function was normal which does not support
TTP or HUS.
Although sepsis was initially suspected and the patient
was started on empiric antibiotics, later it was excluded
because the patient had no evidence of infection, as shown
by normal chest X-ray, urinalysis, urine culture, and blood
cultures.
Liver disease can be either a cause of DIC or a conse-
quence of DIC; the patient had no history of liver disorder;
liver function test remained within normal limit.
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There was no recent change in the patient’s medications,
no reported use of new drugs (other than Quinine), and
no history of over-the-counter medicine use or any herbal
agents.
Antinuclear antibodies (ANA) were negative and lupus
anticoagulant was undetected.
Blood film revealed no abnormal or immature cells to
suspect leukemia.
2.3. Treatment. The patient was admitted to the critical
care unit and treated conservatively. Platelet count, coagu-
lation profile, basic metabolic profile, and electrolytes were
monitored daily. Offending agent (Quinine) was stopped
promptly; she responded well to supportive management
with intravenous hydration with isotonic saline and elec-
trolyte replacement. Broad spectrum antibiotics were started
initially for suspected sepsis but were discontinued after we
obtainednegative results of blood andurine cultures. Platelets
count, PT, INR, and aPTT became within normal limit in five
days of admission. No fresh frozen plasma or cryoprecipitate
was required.
The patient became stable and asymptomatic with sup-
portive treatment; she was discharged in stable condition on
the sixth day of admission. She was strongly advised to avoid
Quinine intake, in the form of tablets or Quinine containing
beverages or herbs.
A six-week follow-up visit to the hematology clinic
showed no evidence of any coagulopathy in her follow-up
blood tests (Table 1).
3. Discussion
For many decades, Quinine remained the mainstay of treat-
ment for nocturnal leg cramps [5–7], and various trials
were done to prove its benefit [8–10]. There are low quality
evidence that quinine (200–500mg/daily) reduces number
of leg cramps per day and moderate quality evidence that
quinine reduces cramp intensity [11]. It is believed that it
decreases the excitability of the motor end-plate, thereby
reducing the muscle contractility [12]. Quinine has been
implicated for some of the grave and life-threatening adverse
events such as thrombocytopenia, hypersensitivity reaction,
and QT interval prolongation [2]. Because it was in use for
decades, prescribers underestimated its side effects. A review
of reports submitted to FDA’s Adverse Event Reporting
System (AERS) from April 2005 to October 2008 showed 38
US cases of serious adverse events associated with Quinine
use. The majority of patients (25) were taking Quinine to
prevent or treat leg cramps or restless leg syndrome; only
one patient was taking Quinine for the treatment of malaria
[13, 14]. Among the 38 reported cases of serious adverse
events, 24 were hematological, 4 cardiovascular, and 10
miscellaneous adverse reactions.The reported hematological
effects were thrombocytopenia, bleeding, TTP, and drug-
induced thrombocytopenia. The FDA, thus, concluded that
the risks of Quinine outweighed any possible benefit for off-
label use and ordered a stop to marketing of this drug for
prevention or treatment of nocturnal leg cramps [15].
In a systematic review of literature by Liles et al. [16], Qui-
nine is a common cause of drug-induced thrombocytopenia
and the most common cause of drug-induced thrombotic
microangiopathy. OtherQuinine-induced systemic disorders
have been described, which include both immune-mediated
and toxic adverse reactions. One hundred and fourteen arti-
cles described 142 patients with definite or probable evidence
for a causal association of Quinine with acute, immune-
mediated reactions. These reactions included chills, fever,
hypotension, painful acral cyanosis, disseminated intravas-
cular coagulation, hemolytic anemia, thrombocytopenia,
neutropenia, acute kidney injury, rhabdomyolysis, liver tox-
icity, cardiac ischemia, respiratory failure, hypoglycemia,
blindness, and toxic epidermal necrolysis. One hundred
and two (72%) reactions were caused by Quinine pills, 28
(20%) by Quinine-containing beverages, and 12 (8%) by five
other types of exposures. Excluding 41 patients who had
only dermatologic reactions, 92 (91%) of 101 patients had
required hospitalization for severe illness; 30 required renal
replacement therapy; three died. Quinine, even with only
minute exposure from common beverages, can cause severe
adverse reactions involving multiple organ systems [16].
Quinine triggers an immune response in susceptible
patients which results in the production of antiplatelet anti-
bodies, as well as antibodies against leukocytes, erythrocytes,
and endothelial cells, which explains the DIC, thrombocy-
topenia, and coagulopathy in such cases [17].
It is imperative to ask specific questions to elicit the
history of Quinine intake in such patients and to remember
that Quinine tablets are not the only source of Quinine for
adverse reactions. Quinine-containing beverages are also a
common source.
The prompt treatment of Quinine-induced DIC, with
early identification and discontinuation of offending drug,
offers an excellent prognosis compared to other adult forms
of coagulopathy [17].
3.1. Learning Points. The conclusions of this study are as
follows:
(i) Quinine is a commonly used remedy for nocturnal leg
cramps, in spite of causing a potential life-threatening
coagulopathy such as DIC and thrombocytopenia.
(ii) Disseminated intravascular coagulation is a rare hem-
atological complication of Quinine, which should
always be remembered in cases of coagulopathy and
DIC, with no clear-cut precipitating etiology.
(iii) In DIC cases, specific questioning regarding Quinine
use is required, as it is believed to be a harmless
and efficient leg cramps remedy by the patients.
There are over-the-counter preparations and herbal
supplements that contain Quinine. Affected patients
should be advised never to take Quinine in any form
including bitter soft drinks or tonic.
(iv) Once diagnosed, prompt discontinuation of Quinine
offers an excellent prognosis of Quinine-induced
DIC, compared to other adult forms of coagulopathy
and DIC.
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(v) Physician’s and community awareness is essential,
regarding the adverse effects associated with Quinine
use. It is still prescribed in the USA, despite FDA’s
warning against off-label use. It should be emphasized
that even small quantity of Quinine present in some
beverages may trigger severe or even life-threatening
side effect.
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